Document is current
Any future updates will be listed below
-
Authors
Bates, Katherine M.
Vathiotis, Ioannis
MacNeil, Tyler
Ahmed, Fahad Shabbir
Aung, Thazin Nwe
Katlinskaya, Yuliya
Bhattacharya, Sabyasachi
Psyrri, Amanda
Yea, Steven
Parkes, Amanda
Sadraei, Nooshin Hashemi
Roychoudhury, Siddhartha
Rimm, David L.
Gavrielatou, Niki
-
Funding
Funding for this research was provided by:
Amgen (GR109016)
- License Information
-
More Information
Article History
Received: 21 October 2022
Accepted: 14 February 2023
First Online: 9 March 2023
Declarations
:
: The need for Informed Consent was waived by the Yale Human Investigation Committee (protocol #9505008219) due to the retrospective nature of the study. The study was approved by the Yale Human Investigation Committee protocol #9505008219 and conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: DLR has served as an advisor for AstraZeneca, Agendia, Amgen, BMS, Cell Signaling Technology, Cepheid, Danaher, Daiichi Sankyo, Novartis, GSK, Konica Minolta, Merck, NanoString, PAIGE.AI, Perkin Elmer, Regeneron, Roche, Sanofi, Ventana and Ultivue. Amgen, Cepheid, Konica Minolta, NavigateBP, NextCure, and Lilly have funded research in his lab. APS has served as an advisor for MSD, Nanobiotics, BMS, Astrazeneca, Merck Serono. She has received institutional research funding from BMS, Merck Serono, Roche, Sanofi. YΚ, SB, SY, APA, NHS and SR are employed by Amgen. Other authors declare that they have no competing interests.
